Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Real-world evaluation of health care resource utilization, clinical effectiveness, and safety of lisocabtagene maraleucel and axicabtagene ciloleucel administered in the outpatient (OP) setting for R/R large B-cell lymphoma (LBCL)

View Full Paper
Ask AI
Bookmark
Share

Authors

SPSagar S. PatelFTFarah ToronSGSameh Gaballa

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows improved safety and reduced hospitalization with outpatient CAR T cell therapy for LBCL, indicating its effectiveness over traditional settings.

Key Points

  • Liso-cel recipients had lower rates of hospitalization compared to axi-cel, enhancing outpatient care feasibility.
  • At 12 months, overall survival was 81.1% for liso-cel versus 70.9% for axi-cel, demonstrating comparable outcomes.
  • This observational analysis utilized the Flatiron Health electronic health record database to evaluate patient outcomes.
  • Findings suggest outpatient CAR T cell therapy could alleviate inpatient treatment burdens and improve patient access.

Cite This Study

Patel et al. (2025) studied this question.

synapsesocial.com/papers/69362f6c4fa91c937236e057https://doi.org/10.1182/blood-2025-6270
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Outpatient (OP) use of lisocabtagene maraleucel (liso-cel) in patients (Pts) with relapsed or refractory (R/R) large B-cell lymphoma (LBCL): Real-world data from the CIBMTR registry2025
  2. 2Comparative real-world outcomes of CD19-directed CAR T-cell therapies in large B-cell lymphoma2025 · 23 citations
  3. 3Axi-cel vs. tisa-cel vs. liso-cel in R/R DLBCL: Meta-analysis of the efficacy-safety trade-off.2026
  4. 4Comparison of axicabtagene ciloleucel to standard regimens as second line treatment for large B cell lymphoma in real life: A lysa study from descar-T and realysa registries2025
  5. 5Efficacy and safety of lisocabtagene maraleucel monotherapy in relapsed or refractory large B-cell lymphoma: A systematic review and meta-analysis of clinical trials and real-world studies2025 · 1 citations